• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Memory Pharmaceuticals

edit

Memory Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery and development of drug candidates for the treatment of central nervous system conditions. It offers drugs for neurological diseases associated with aging, such as Alzheimer’s disease, as well as psychiatric disorders, such as schizophrenia, cognitive impairment associated with schizophrenia (CIAS), and depression.

The company was incorporated in 1997 and is based in Montvale, New Jersey. As of December 31, 2008, Memory Pharmaceuticals Corp. operates as a subsidiary of Hoffmann-La Roche Inc.

Milestones

edit

• 
  Memory Pharmaceuticals added Jonathan J. Fleming as Co-founder.
  Posted 9/9/09 at 6:04pm
• 
  Memory Pharmaceuticals added Vaughn M. Kailian as CEO.
  Posted 9/9/09 at 6:04pm
• 
  Memory Pharmaceuticals received $31M in Venture Round funding. (9/21/05)
  Posted 4/20/10 at 8:20pm via oxbio.com
• 
  Memory Pharmaceuticals received $10M in Venture Round funding. (3/29/07)
  Posted 3/13/10 at 4:01am via marketwatch.com
• 
  Memory Pharmaceuticals was acquired by Hoffmann-La Roche for $62.9M. (11/25/08)
  Posted 9/9/09 at 6:14pm via rocheusa.com

Videos

Screenshots

edit

Sources

1. Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals (rocheusa.com) [edit]
2. Memory Pharmaceuticals Announces $31 Million Financing (oxbio.com) [edit]
3. Memory Pharma gets $10 mln in financing (marketwatch.com) [edit]